UCB Reports - Industry Research
Reports Featuring UCB
Neurodegenerative Disease Market
The Neurodegenerative Disease Market size is estimated at USD 55.12 billion in 2024, and is expected to reach USD 77.82 billion by 2029, growing at a CAGR of 7.14% during the forecast period (2024-2029).
Epilepsy Drugs Market
The epilepsy drugs market is projected to register a CAGR of 3.5% during the forecast period.
Restless Legs Syndrome Market
The Restless Legs Syndrome Market size is estimated at USD 691.55 million in 2024, and is expected to reach USD 891.44 million by 2029, growing at a CAGR of 5.21% during the forecast period (2024-2029).
Global Cytokine Market
The cytokine market is expected to register a CAGR of 6.2% during the forecast period (2022-2027).
Myasthenia Gravis Therapeutics Market
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness.
Global Monoclonal Antibody Therapeutics Market
The monoclonal antibody therapeutics market studied was anticipated to grow with a CAGR of nearly 13.2% during the forecast period.
TNF Inhibitors Market
The TNF Inhibitors Market studied was anticipated to grow with a CAGR of nearly 9.5% during the forecast period.
Ankylosing Spondylitis Treatment
The Ankylosing Spondylitis Treatment Market size is estimated at USD 6.64 billion in 2024, and is expected to reach USD 9.72 billion by 2029, growing at a CAGR of 7.75% during the forecast period (2024-2029).
Global Axial Spondyloarthritis (axSpA) Market
The Axial Spondyloarthritis market is projected to register a CAGR of 7.37% during the forecast period (2022-2027).
Other Reports Covering UCB
Pharmaceuticals
- Ankylosing Spondylitis Treatment
- Epilepsy Drugs Market
- Global Axial Spondyloarthritis (axSpA) Market
- Global Psoriasis Drugs Market
- Inflammatory Bowel Disease (IBD) Therapeutics Market
- Myasthenia Gravis Therapeutics Market
- Neurodegenerative Disease Market
- Psoriatic Arthritis Therapeutics Market
- TNF Inhibitors Market
